Merck and GlaxoSmithKline Collaborate on Pazopanib

December 19, 2013
Melanie Sena

Melanie Sena is community editor of Pharmaceutical Technology.

Merck and GlaxoSmithKline begin clinical trial of pazopanib for the treatment of advanced renal-cell carcinoma.

Merck & Co. announced the initiation of a clinical trial to evaluate the combination of the company’s investigational anti-PD-1 immunotherapy, MK-3475, and GlaxoSmithKline’s (GSK) orally administered kinase inhibitor, pazopanib, for the treatment of advanced renal-cell carcinoma.

Merck and GSK entered a collaboration to study MK-3475 with pazopanib and other agents in the GSK portfolio. This Phase I and Phase II clinical trial is designed to evaluate the safety and efficacy of a combination of MK-3475 and pazopanib in treatment naïve patients with advanced renal-cell carcinoma.

Source: Merck & Co.